Corvus Pharmaceuticals, Inc.
CRVS
$7.60
-$0.22-2.81%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 74.74% | -87.66% | 366.50% | -82.07% | -570.28% |
| Total Depreciation and Amortization | 33.33% | 38.10% | -4.35% | -28.57% | -30.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -96.70% | -0.86% | -7,924.50% | 175.12% | 2,793.40% |
| Change in Net Operating Assets | -498.55% | 630.83% | -30.59% | -273.15% | 121.90% |
| Cash from Operations | -51.34% | -5.40% | -60.23% | -63.83% | -16.32% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 32.70% | -15.33% | 61,228.57% | -162.64% | -122.17% |
| Cash from Investing | 32.70% | -15.98% | 60,714.29% | -162.42% | -122.17% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 620.00% | 118.04% | -- | -- | -85.07% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 620.00% | 17.78% | -- | -- | -85.07% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.37% | 31.24% | 27.56% | 154.24% | -181.63% |